Phase II study of XXXX , @entity136 and @entity1487 in advanced @entity788 .

@entity1 @entity788 @entity137 @entity417 @entity882 @entity900 @entity33 @entity1398 @entity158 @entity136 @entity1487
BACKGROUND: The aim of this study was to determine the activity of the combination of @entity900 , @entity136 and @entity1487 ( @entity1487 ) as therapy for metastatic or locally advanced inoperable @entity788 . @entity1 AND METHODS: @entity1 with histologically proven advanced or metastatic @entity788 received first-line chemotherapy comprising @entity900 (20 mg/m2 on days 1, 8, 15, 22, 29 and 36), @entity136 (1000 mg/m2 on days 1, 8, 29 and 36) and @entity1487 (200 mg/m2 as continuous infusion on days 1-42) every 56 days. RESULTS: A total of 34 @entity1 were studied. Eighty courses were administered (median two courses per @entity1 ). Among 32 @entity1 evaluable for response, two @entity1 had a complete response and four a partial response for an overall response rate of 19% (95% confidence interval 7% to 36%). Thirteen @entity1 had stable disease (40%) and 13 progressed. Median progression-free survival was 4.7 months, median survival 9.0 months and 26% of @entity1 achieved 1-year survival. Ten of 25 @entity1 (40%) with @entity158 at presentation had a sustained reduction of analgesic consumption. The principal grade 3/4 @entity137 were @entity1398 , @entity882 , @entity417 and @entity33 , occurring in 24%, 21%, 9% and 3% of @entity1 . CONCLUSION: This schedule seems well tolerated and active in @entity788 and worthwhile of further evaluation.
